Business Context and Reporting Period
This Form 8-K is filed by Entero Therapeutics, Inc. (not Gridai Technologies Corp.) on August 9, 2025, reporting events occurring on that date with a closing scheduled for August 11, 2025. The company is a clinical-stage biotechnology firm incorporated in Delaware, trading on the Nasdaq Capital Market under the symbol ENTO.
Key Financial Metrics and Transaction Details
- Gross Proceeds: Approximately $3,000,000 from a private placement.
- Securities Issued:
- 4,878,841 Pre-Funded Warrants (exercise price $0.00001).
- 9,757,682 Common Stock Purchase Warrants (exercise price $0.3649).
- 200,000 Consulting Warrants (purchase price $0.125 per warrant).
- Combined Unit Price: $0.6149 for one Pre-Funded Warrant and two Common Warrants.
- Use of Proceeds: General corporate purposes, working capital, and repayment of certain outstanding liabilities.
- Payment Schedule: $1,000,000 at closing; remaining $2,000,000 upon effectiveness of the Registration Statement.
- Director Compensation: New directors appointed will receive $2,500 per month in cash compensation.
Note: This filing does not provide specific revenue, profit, cash flow, margin, or total debt figures for the company.
Material Changes and Governance
- Capital Structure: Significant dilution potential via the issuance of over 14.6 million warrants (excluding consulting warrants).
- Board Composition: Appointment of two new directors, Geordan Pursglove and Jason Sawyer, effective August 11, 2025.
- Lock-Up Provisions: Officers and directors are restricted from selling shares for 90 days post-closing. Purchasers are restricted from exercising warrants to exceed 4.99% (or 9.99% if elected) beneficial ownership.
- Issuance Moratorium: The Company is restricted from issuing new equity or filing registration statements for as long as any Purchaser holds 30% of the securities purchased.
Outlook, Risks, and Contingencies
- Registration Rights: The Company must file a resale registration statement within 15 days of closing and seek effectiveness promptly.
- Cashless Exercise: Purchasers may exercise Common Warrants on a cashless basis if the underlying shares are not registered.
- Board Control: Purchasers have the right to designate two board members as long as they beneficially own at least 10% of outstanding common stock (on a fully diluted basis).
- Exemption Reliance: The offering relies on Section 4(a)(2) of the Securities Act of 1933 as a transaction not involving a public offering.
Investor Verification Checklist
- Verify the exact closing date and receipt of the initial $1,000,000 tranche.
- Confirm the filing and effectiveness status of the resale Registration Statement required for the remaining $2,000,000 proceeds.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific adjustment mechanisms and anti-dilution provisions.
- Assess the impact of the 90-day insider lock-up and the 30% issuance moratorium on future capital raising capabilities.
- Check the company's current cash position and outstanding liabilities to gauge the immediate impact of the "repayment of certain outstanding liabilities" use of proceeds.